The generic injectable market in the United States is experiencing substantial expansion, driven by increasing demand for cost-effective biologics, a surge in chronic disease cases, and supportive biosimilar regulatory policies. Growing at a steady compound annual growth rate (CAGR) of 6.1%, the market is expected to reach USD 69.2 million by 2035, up from USD …